Literature DB >> 2964980

Elevated urinary prostaglandin excretion and the effect of indomethacin on renal function in incipient diabetic nephropathy.

E R Mathiesen1, E Hommel, U B Olsen, H H Parving.   

Abstract

We investigated whether the glomerular synthesis of prostaglandins modulates the glomerular filtration rate and urinary albumin excretion in incipient diabetic nephropathy (defined as urinary albumin excretion between 30 and 300 mg/24 h (microalbuminuria) in two out of three sterile ketone-free 24-h urine collections in patients having insulin-dependent diabetes mellitus (IDDM) without hypertension or other kidney disease). The urinary excretion of prostaglandin E2 was significantly elevated in 8 insulin-dependent diabetic patients with incipient nephropathy as compared with 9 normoalbuminuric IDDM patients and 11 healthy controls: 317 (182-1273); 95 (67-225); 132 (54-263) pg/min, respectively (2p less than 0.01). Glomerular filtration rate (single bolus 51Cr-EDTA technique) and albuminuria (radioimmunoassay) were measured twice within 2 weeks in 8 females having IDDM with incipient nephropathy. The study design was a randomized double-blind trial with the patients receiving either indomethacin (150 mg/day) or placebo for 3 days prior to the kidney function studies. Indomethacin treatment induced a significant reduction in urinary prostaglandin E2 excretion (73%) (2p less than 0.01), urinary albumin excretion rate diminished from 207 (63-253) to 87 (49-147) mg/24 h (2p less than 0.01), fractional clearance of albumin declined (70%) (2p less than 0.01). Glomerular filtration rate remained stable (108 (88-133) versus 110 (95-142) ml/min). Blood glucose and blood pressure were comparable during the placebo and indomethacin treatment (12.6 +/- 3 versus 13.4 +/- 5 mmol/l and 122/79 +/- 3/9 versus 122/82 +/- 4/10 mmHg, respectively). Our results suggest that enhanced glomerular synthesis of vasodilating prostaglandins may accelerate microalbuminuria in incipient diabetic nephropathy.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2964980     DOI: 10.1111/j.1464-5491.1988.tb00961.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  8 in total

1.  Plasma lipoproteins and renal function during simvastatin treatment in diabetic nephropathy.

Authors:  E Hommel; P Andersen; M A Gall; F Nielsen; B Jensen; P Rossing; J Dyerberg; H H Parving
Journal:  Diabetologia       Date:  1992-05       Impact factor: 10.122

2.  Long-term effects of linoleic-acid-enriched diet on albuminuria and lipid levels in type 1 (insulin-dependent) diabetic patients with elevated urinary albumin excretion.

Authors:  R P Dullaart; B J Beusekamp; S Meijer; K Hoogenberg; J J van Doormaal; W J Sluiter
Journal:  Diabetologia       Date:  1992-02       Impact factor: 10.122

3.  Microalbuminuria and coronary heart disease in non-diabetics.

Authors:  D Buggy; J Feely; J Murphy; C O'Sullivan; M Walsh
Journal:  Postgrad Med J       Date:  1993-09       Impact factor: 2.401

4.  Efficacy of captopril in postponing nephropathy in normotensive insulin dependent diabetic patients with microalbuminuria.

Authors:  E R Mathiesen; E Hommel; J Giese; H H Parving
Journal:  BMJ       Date:  1991-07-13

Review 5.  Current therapeutic management of diabetic nephropathy.

Authors:  S M Kohler; B K Krämer
Journal:  Acta Diabetol       Date:  1994-09       Impact factor: 4.280

6.  Urinary prostaglandin E2 is a biomarker of early adaptive hyperfiltration in solitary functioning kidney.

Authors:  Tarak Srivastava; Wenjun Ju; Ginger L Milne; Mohamed H Rezaiekhaligh; Vincent S Staggs; Uri S Alon; Ram Sharma; Jianping Zhou; Ashraf El-Meanawy; Ellen T McCarthy; Virginia J Savin; Mukut Sharma
Journal:  Prostaglandins Other Lipid Mediat       Date:  2019-12-12       Impact factor: 3.813

Review 7.  Nonsteroidal Anti-Inflammatory Drugs and the Kidney.

Authors:  Walter H Hörl
Journal:  Pharmaceuticals (Basel)       Date:  2010-07-21

8.  Prospective analysis of the efficacy of beraprost sodium combined with alprostadil on diabetic nephropathy and influence on rennin-angiotensin system and TNF-α.

Authors:  Xinwei Xu; Xiaojing Pan; Song Li
Journal:  Exp Ther Med       Date:  2019-12-02       Impact factor: 2.447

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.